News

Notice of Convocation of the 161st Annual General Meeting of Shareholders

Positive Interim Analysis Results from Phase 3 Clinical Trial of Tapinarof Cream 0.5%, Aryl Hydrocarbon Receptor (AhR) Modulating Agent, in Infant Patients with Atopic Dermatitis in Japan

Notice transcript of FY 2025 financial result meeting

New England Journal of Medicine Publishes Shionogi Study Demonstrating Ensitrelvir Prevents COVID-19 Following Exposure

Financial Results and Supplement for FY2025

Presentation Materials for FY2025 financial results

Shionogi Joins the World Economic Forum and Signs the Davos Compact on Antimicrobial Resistance - Contributing to the resolution of global healthcare challenges, including AMR, through international collaboration-

Notice Regarding the Absorption-Type Merger of Torii Pharmaceutical Co., Ltd., a Wholly Owned Subsidiary

Notice of Revisions to Dividend Forecasts (Dividend Increase)

Shionogi Announces Investment in Restore Vision Inc. through Its CVC Activities

Shionogi Selected as a “DX Stock 2026”

Shionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threats

ESCMID Global 2026: Shionogi presents new real-world data highlighting clinical effectiveness of Fetroja®/Fetcroja® (cefiderocol) in MBL-producing Enterobacterales infections

Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone)

GSK, Pfizer and Shionogi complete changes to ViiV Healthcare shareholding

SHIONOGI Group’s Efforts to Address AMR Highly Rated -Ranked No. 2 Among Global R&D-Based Pharmaceutical Companies in the Antimicrobial Resistance Benchmark 2026-

Notice Regarding Bridge Loan Financing in Connection with an Additional Investment in ViiV Healthcare Ltd

Notice Regarding the Consolidation of Shionogi‑Apnimed Sleep Science, LLC as a Subsidiary of Shionogi

Notice regarding the Bridge Loan Financing Related to Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS® (edaravone) and IV RADICAVA

Shionogi Announces Approval in Japan of a Supplemental Indication for XOCOVA® (Ensitrelvir Fumaric Acid) for the Post-Exposure Prophylaxis of COVID-19.

Shionogi Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-Onset Pompe Disease

ZURZUVAE® Capsules 30 mg for the Treatment of Major Depressive Disorder launched in Japan

Application for Manufacturing and Marketing Approval of a New Lotion Formulation for the Atopic Dermatitis Treatment "CORECTIM®" in Japan

Notice of the Candidate for Director

Notice Regarding the Determination of the Basic Policy for the Absorption-Type Merger of TORII PHARMACEUTICAL Co., Ltd.

Shionogi Announces Corporate Reorganization and Personnel Reassignment (Effective April 1, 2026)

Shionogi Notes Torii Pharmaceutical’s Announcement on the Launch of YCANTH® topical solution 0.71% for the Treatment of Molluscum Contagiosum in Japan

Presentation Materials for FY2025 3Q financial results

Financial Results and supplement for FY2025 3Q

GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding

Shionogi Awarded the Minister of Health, Labour and Welfare Award for Cefiderocol at the 8th Japan Medical Research and Development Grand Prize

Approval for Cefiderocol in China